Roche has again sweetened its offer for Genentech – this time by about 2% to $46.7bn – as it pushes to take full control of the biotech company after an eight-month courtship, reports Reuters. Roche’s $95 per share offer on Monday marks the second increase since Friday, when Roche raised its direct tender offer to shareholders to $93 a share. Switzerland-based Roche has been trying since July to acquire the 44% of Genentech it does not already own.

This entry was posted by Gwen Robinson on Tuesday, March 10th, 2009 at 5:04 and is filed under Capital markets, M&A. Tagged with genentech, Roche. Edit this entry.